Laura Sepp-Lorenzino

CSO @Intelliatx
🇺🇸🇦🇷 #GeneEditing #CRISPR #WomenInSTEM
Opinions/likes/RT mine & not endorsements.

[Laura Sepp-Lorenzino @LauraSepplore]

Thrilled to be back on the board of @OTSociety and honored to be President Elect for 2028-2029.
Awesome to work with @Rebecca Miles, Alexis Secka, the board and our #OTS community to accelerate oligo Rx breakthroughs!

[Oligonucleotide Therapeutics Society @OTSociety]

Thank you to all our members who voted in the recent election!

We are pleased to announce the new OTS BOD for the 2026-2027 term.

2026-2027 OTS Board of Directors

Learn more about our new BOD at
https://t.co/DJqSpfGnHM

#ots #oligotherapeutics #oligonucleotidetherapeutics

[Oligonucleotide Therapeutics Society @OTSociety]

Thank you to all our members who voted in the recent election!

We are pleased to announce the new OTS BOD for the 2026-2027 term.

2026-2027 OTS Board of Directors

Learn more about our new BOD at
https://t.co/DJqSpfGnHM

#ots #oligotherapeutics #oligonucleotidetherapeutics

[Laura Sepp-Lorenzino @LauraSepplore]

I am honored to join the Board of @ask_bio Inc. during such a pivotal moment as it advances its clinical and pre-clinical programs toward major milestones. Eager to help realize the full potential of these groundbreaking medicines!
#CGT #genetherapy #AAV #BOD

[AskBio Inc. (AskBio) @ask_bio]

We’re proud to welcome Dr. Laura Sepp-Lorenzino to AskBio’s Board of Directors! With 30+ years of leadership in biotech, her insights will be key as we advance our clinical and pre-clinical #GeneTherapy candidates.

Learn more: https://t.co/gnSCatDoOr
#AskBio #Leadership

[Intellia Therapeutics @intelliatx]

$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: https://t.co/iEIsTjLvXK

#CRISPR #GeneEditing

[Laura Sepp-Lorenzino @LauraSepplore]

We made the tough call to restructure our business operations, affecting many of our skilled colleagues. I am committed to supporting them through this transition and serving as a personal reference where I can. Your consideration is greatly appreciated. #ONEintellia #talent

[Intellia Therapeutics @intelliatx]

$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: https://t.co/iEIsTjLvXK

#CRISPR #GeneEditing

[Laura Sepp-Lorenzino @LauraSepplore]

@JMaraganore Happy 2025!!!

[Laura Sepp-Lorenzino @LauraSepplore]

Wishing you a year filled with positivity, creativity, and a commitment to making the world a better place. Let's embrace each day with a spirit of discovery and a drive to create beauty around us. Here's to a year of growth, kindness, and meaningful contributions. #NewYear2025

[Laura Sepp-Lorenzino @LauraSepplore]

nex z NEJM article: https://t.co/Ilki3bTq6W

[Laura Sepp-Lorenzino @LauraSepplore]

Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia

[Laura Sepp-Lorenzino @LauraSepplore]

Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia

[Intellia Therapeutics @intelliatx]

#ATTR News: $NTLA announces positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with #ATTR amyloidosis with cardiomyopathy. Full details here: https://t.co/RP20Uz8GLR. Join us at 12 p.m. ET for a webcast discussing the data, as well as an update from the ongoing Phase 1 polyneuropathy cohort. https://t.co/hufx97doY8
#CRISPR #GeneEditing

[Laura Sepp-Lorenzino @LauraSepplore]

This encouraging data update brings us one step closer to making CRISPR-based medicines a reality through innovative science. Excited for the future as we continue to move forward!
#HAE #CRISPR #OneIntellia

[Intellia Therapeutics @intelliatx]

#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: https://t.co/Uao5j83Wd6

[Intellia Therapeutics @intelliatx]

#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: https://t.co/Uao5j83Wd6

[Laura Sepp-Lorenzino @LauraSepplore]

Round of applause to the $NTLA team today!
Great news from our #AATDProgram Congratulations!
#CRISPR #GeneEditing

[Intellia Therapeutics @intelliatx]

NEWS: $NTLA receives authorization by the @MHRAgovuk to initiate a Phase 1/2 of NTLA-3001 for the treatment of #alpha1 antitrypsin deficiency-associated lung disease. This is Intellia's first wholly owned in vivo gene insertion program. https://t.co/exgjWzqqhv
#CRISPR #AATD

[Laura Sepp-Lorenzino @LauraSepplore]

Thank you @bradloncar for the opportunity to talk about how $NTLA is advancing the field of #geneediting medicines!

[BiotechTV @BiotechTV]

Company News: @intelliatx's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA

Full video: https://t.co/CAcs7uYlsW

[Laura Sepp-Lorenzino @LauraSepplore]

What a great time to be at Intellia! More good news from our NTLA-2002 program for #hereditaryangioedema. Congrats to the team! #CRISPR #OneIntellia

[Intellia Therapeutics @intelliatx]

Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at @EAACI_HQ 2024 Congress. Full details here: https://t.co/HApgVmi8ds
#HAE #CRISPR #geneediting

[Laura Sepp-Lorenzino @LauraSepplore]

Heartfelt congratulations to Professor José M. Polo on being elected as Fellow of the Australian Academy of Sciences!!!
https://t.co/nW3MyUnAZj
Learn more about José's research here: https://t.co/94yFYxmoXU

I’m so proud of you!!! #proudaunt

[Laura Sepp-Lorenzino @LauraSepplore]

Significant milestone achieved! Our first patient has been dosed in the MAGNITUDE study for #ATTR. Congrats to the team!
#CRISPR #GeneEditing

[Intellia Therapeutics @intelliatx]

#ATTR News: Intellia doses the first patient in its Phase 3 MAGNITUDE study of NTLA-2001 for the potential treatment of #transthyretinamyloidosis with cardiomyopathy: https://t.co/lyHPaGe0cE

#GeneEditing #CRISPR

[Laura Sepp-Lorenzino @LauraSepplore]

Delivery, delivery, delivery!
Join us in Siracusa, Italy from April 4-7 to discuss new advances in nucleic acid delivery and how to solve the remaining challenges! Don't miss this opportunity. Abstract deadline is March 15, 2024. Register here:
https://t.co/qRw03d7LKU

[Intellia Therapeutics @intelliatx]

$NTLA News: This morning, Intellia announced a strategic collaboration with @ReCodeTx to develop novel #geneeditingtherapies for #cysticfibrosis. Full details here: https://t.co/FpBQ9VSdb2

#CRISPR #CF

[Laura Sepp-Lorenzino @LauraSepplore]

Two for two! Congrats to the team on our second @NEJM publication demonstrating the promise of #CRISPR!

[Intellia Therapeutics @intelliatx]

Huge congratulations to @VertexPharma and @CRISPRTX for making history with the first-ever FDA approval of a #CRISPR therapy!